Q-omics provides the consensus-scored TRIM6-TRIM34 profile across patient tissues and cancer cell-line models. TRIM6-TRIM34 expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, TRIM6-TRIM34 is differentially expressed in 4, with the highest sampling consensus in KICH. Additionally, TRIM6-TRIM34 RNA expression shows 7,751 significant gene co-expression associations, with the highest sampling consensus in PCPG. Together, these results highlight LUAD, KICH, and PCPG as cancer lineages where TRIM6-TRIM34 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TRIM6-TRIM34 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TRIM6-TRIM34 survival associations across molecular data types. TRIM6-TRIM34 RNA expression shows survival associations in the most cancer types (16), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TRIM6-TRIM34 RNA expression–survival associations across cancer types. High TRIM6-TRIM34 expression shows unfavorable associations in LUAD, COAD, GBM and LIHC, but favorable associations in BLCA and KIRC. The LUAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUAD as the clearest survival context for TRIM6-TRIM34 RNA expression.
This table summarizes TRIM6-TRIM34 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for TRIM6-TRIM34. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TRIM6-TRIM34 shows lower tumor expression in KICH, PRAD and KIRP and higher tumor expression in THCA. The KICH box plot shows higher TRIM6-TRIM34 RNA expression in normal versus tumor tissue (log2 FC = −0.032, t-test p = .043).
This table shows molecular features associated with TRIM6-TRIM34 in patient tissues and cancer cell lines. In patient samples, TRIM6-TRIM34 shows the broadest associations at the RNA and protein expression levels, with PCPG recurring as the lineage with the largest associated feature set. In cancer cell lines, TRIM6-TRIM34 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in BREAST and LARGE_INTESTINE.
